Proliferative Diabetic Retinopathy Clinical Trial
— LASERLESSOfficial title:
Endolaserless Vitrectomy With Intravitreal Aflibercept Injection for Proliferative Diabetic Retinopathy-Related Vitreous Hemorrhage (LASER LESS TRIAL)
This is a phase I/II open label, randomized, interventional clinical trial. Study eyes will receive one preoperative intravitreal aflibercept injection (IAI) <21 days but >7 days prior to vitrectomy and one intraoperative IAI at end of surgery followed by randomization in a 1:1 ratio into either 4 mandatory postoperative q4weeks IAI followed by mandatory q8 weeks IAI for 52 weeks follow-up (q8 week Group) or 2 mandatory postoperative q4weeks IAI followed by mandatory q16 weeks IAI for 52 weeks follow-up (q16 week Group).
Status | Recruiting |
Enrollment | 24 |
Est. completion date | June 2018 |
Est. primary completion date | June 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Adults age >18 years with Diabetes Mellitus 2. PDR- related vitreous hemorrhage and not of another cause 3. BCVA Vision LP or better 4. Investigator determination that vitrectomy indicated for PDR-related vitreous hemorrhage 5. Willing and able to comply with clinic visits and study-related procedures 6. Provide HIPPA and signed informed consent prior to any study procedures Exclusion Criteria: 1. A condition per investigator opinion, would preclude participation in the study (unstable medical status, cardiovascular disease, glycemic control, inability to follow up etc.) 2. Participation in an investigational trial within 30 days of enrollment 3. Known allergy to IAI 4. Systemic anti-VEGF or pro-VEGF treatment within 4 months of enrollment 5. For women of childbearing age, pregnant or lactating or intending to become pregnant within the next 3 years 6. History of PRP or peripheral retinal cryopexy or peripheral retinopexy for any reason in the study eye 7. History of vitrectomy in the study eye 8. History or evidence for rhegmatogenous retinal detachment in the study eye 9. Evidence of traction retinal detachment involving or threatening central macula in the study eye 10. Exam evident of external ocular infection (i.e. conjunctivitis, significant blepharitis, chalazion etc) 11. Intravitreal anti-VEGF injection in the study eye <4weeks from enrollment. 12. Pregnant or breast-feeding women 13. Sexually active men* or women of childbearing potential** who are unwilling to practice adequate contraception during the study (adequate contraceptive measures include stable use of oral contraceptives or other prescription pharmaceutical contraceptives for 2 or more menstrual cycles prior to screening; intrauterine device [IUD]; bilateral tubal ligation; vasectomy; condom plus contraceptive sponge, foam, or jelly, or diaphragm plus contraceptive sponge, foam, or jelly) *Contraception is not required for men with documented vasectomy. **Postmenopausal women must be amenorrheic for at least 12 months in order not to be considered of child bearing potential. Pregnancy testing and contraception are not required for women with documented hysterectomy or tubal ligation. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Southeast Retina Center, PC | Augusta | Georgia |
Lead Sponsor | Collaborator |
---|---|
Southeast Retina Center, Georgia |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | • Ocular and systemic safety evaluation for adverse events at any time point through 52 weeks: | Examples include worsened acuity >30 letters, rhegmatogenous or tractional retinal detachment, endophthalmitis, new or increased vitreous hemorrhage, cataract progression or surgery, need for additional vitrectomy or scleral buckle, development of new DME after OCT documentation of absence of DME, systemic thromboembolic events, deaths and systemic serious adverse events at any time point through week 52. | Through 52 weeks from Baseline | No |
Secondary | Mean change in BCVA letter score | Mean change in BCVA letter score over time through week 52 | 52 weeks from Baseline | No |
Secondary | Mean BCVA letter score | Mean BCVA letter score over time through week 52 | 52 weeks from Baseline | No |
Secondary | Proportion of eyes with progression of PDR | Proportion of eyes with progression of PDR as defined above at any time point through week 52 | Through 52 weeks from Baseline | No |
Secondary | Mean OCT CSF thickness | Mean OCT CSF thickness over time through week 52 | Through 52 weeks from Baseline | No |
Secondary | Proportion of eyes with OCT CSF thickness <300um | Proportion of eyes with OCT CSF thickness <300um at week 52 | Through 52 weeks from Baseline | No |
Secondary | Proportion of eyes with absence of Optos widefield fluorescein angiographic macular leakage | Proportion of eyes with absence of Optos widefield fluorescein angiographic macular leakage at week 52 | Through 52 weeks from Baseline | No |
Secondary | Proportion of eyes with absence of active neovascularization | Proportion of eyes with absence of active neovascularization by Optos widefield fluorescein angiography at week 52 | Through 52 weeks from Baseline | No |
Secondary | Proportion of eyes with absence of active neovascularization | Proportion of eyes with absence of active neovascularization by 7 standard field photography at week 52 | Through 52 weeks from Baseline | No |
Secondary | Proportion of eyes with unchanged, worsened, or improved fluorescein angiographic macular leakage | Proportion of eyes with unchanged, worsened, or improved fluorescein angiographic macular leakage from baseline angiograms at week 52 | Through 52 weeks from Baseline | No |
Secondary | Proportion of eyes with unchanged, worsened, or improved fluorescein angiographic neovascularization | Proportion of eyes with unchanged, worsened, or improved fluorescein angiographic neovascularization from baseline angiograms at week 52 | Through 52 weeks from Baseline | No |
Secondary | Proportion of eyes with unchanged, worsened, or improved fundus photographic DME appearance | Proportion of eyes with unchanged, worsened, or improved fundus photographic DME appearance from baseline photographs at week 52 | Through 52 weeks from Baseline | No |
Secondary | Mean cumulative score and change for the combined 30-2 and 60-4 HVF test | Mean cumulative score and change for the combined 30-2 and 60-4 HVF test from week 4 to week 52. | Through 52 weeks from Baseline | No |
Secondary | Proportion of eyes requiring additional IAI other than mandatory injections | Proportion of eyes requiring additional IAI other than mandatory injections through week 52 | Through 52 weeks from Baseline | No |
Secondary | Proportion of eye with progression of PDR requiring rescue PRP standard of care | Proportion of eye with progression of PDR requiring rescue PRP standard of care at any time point through 52 weeks | Through 52 weeks from Baseline | No |
Secondary | Proportion of eyes requiring PRP or retinopexy | Proportion of eyes requiring PRP or retinopexy through week 52 | Through 52 weeks from Baseline | No |
Secondary | Proportion of eyes requiring additional vitrectomy | Proportion of eyes requiring additional vitrectomy through week 52 | Through 52 weeks from Baseline | No |
Secondary | Proportion of enrolled eyes requiring intraoperative endolaser in a PRP pattern at the time of initial vitrectomy | Proportion of enrolled eyes requiring intraoperative endolaser in a PRP pattern at the time of initial vitrectomy | Through 52 weeks from Baseline | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01921192 -
Effect of Folic Acid, Vitamin B6 and Vitamin B12 in Diabetic Retinopathy
|
Phase 4 | |
Recruiting |
NCT01044875 -
Trial of Yellow 577 nm Laser Versus Green 532 nm Laser for Proliferative Diabetic Retinopathy
|
N/A | |
Active, not recruiting |
NCT00993525 -
Intravitreal Ranibizumab For Persistent New Vessels In Diabetic Retinopathy(Inipe Study)
|
Phase 1/Phase 2 | |
Completed |
NCT01307072 -
Compliance to Ophthalmic Follow-up Examinations and Surgical Outcome for Proliferative Diabetic Retinopathy
|
N/A | |
Completed |
NCT01758757 -
Comparison of Small-gauge Vitrectomy and Conventional Vitrectomy for Proliferative Diabetic Retinopathy
|
N/A | |
Withdrawn |
NCT00600236 -
HLA and it Relation With the Development of Proliferative Diabetic Retinopathy in Mexican Population
|
Phase 3 | |
Completed |
NCT05414149 -
Efficacy and Safety Comparison of IVR and IVC Before Vitrectomy in Proliferative Diabetic Retinopathy
|
N/A | |
Completed |
NCT05408416 -
Comparison of Surgery Outcome Between Preoperative IVR and Intraoperative IVR in PPV for PDR
|
N/A | |
Not yet recruiting |
NCT04464694 -
Pre-vitrectomy Intravitreal Ranibizumab for Patients With Proliferative Diabetic Retinopathy Combined With Diabetic Macular Edema
|
Phase 4 | |
Not yet recruiting |
NCT03633266 -
Anti-VEGF Instead of Intraoperative PRP in Proliferative Diabetic Retinopathy
|
N/A | |
Completed |
NCT03490318 -
Effectiveness of Multimodal Imaging for the Evaluation of Retinal Oedema And New vesseLs in Diabetic Retinopathy
|
||
Completed |
NCT01627977 -
Association of Lutein, Zeaxanthin and Brilliant Blue in Chromovitrectomy
|
Phase 3 | |
Completed |
NCT00776763 -
Ocular Growth Factors Profile in Proliferative Retinopathies Before and After Intravitreal Bevacizumab
|
Phase 2 | |
Terminated |
NCT00563628 -
Changes in Macular Thickness After Patterns Scan Laser
|
Phase 4 | |
Terminated |
NCT00563043 -
Changes in Electroretinogram and Contrast Sensitivity After PASCAL Treatment
|
Phase 4 | |
Completed |
NCT00682240 -
Morphological and Functional Retinal Changes Following Retinal Photocoagulation
|
Phase 4 | |
Completed |
NCT00446381 -
Effect of Macugen(Pegaptanib)on Surgical Outcomes and VEGF Levels in Diabetic Patients With PDR (Diabetic Retinopathy or CSDME (Macular Edema)
|
N/A | |
Completed |
NCT02879422 -
Genetic Markers and Proliferative Diabetic Retinopathy
|
N/A | |
Enrolling by invitation |
NCT02911311 -
Conbercept vs Panretinal Photocoagulation for the Management of Proliferative Diabetic Retinopathy
|
N/A | |
Recruiting |
NCT05514925 -
Cryoapplication Versus Anti-VEGF Before Diabetic Vitrectomy
|
Phase 4 |